Vaughan Nelson Investment Management L.P. Has $36.72 Million Holdings in PRA Health Sciences Inc (PRAH)

Vaughan Nelson Investment Management L.P. lessened its position in shares of PRA Health Sciences Inc (NASDAQ:PRAH) by 21.4% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 333,229 shares of the medical research company’s stock after selling 90,715 shares during the period. Vaughan Nelson Investment Management L.P. owned about 0.51% of PRA Health Sciences worth $36,718,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Carnegie Capital Asset Management LLC grew its holdings in PRA Health Sciences by 0.9% during the 2nd quarter. Carnegie Capital Asset Management LLC now owns 59,966 shares of the medical research company’s stock worth $6,083,000 after acquiring an additional 556 shares in the last quarter. Strs Ohio grew its holdings in PRA Health Sciences by 14.2% during the 3rd quarter. Strs Ohio now owns 4,582 shares of the medical research company’s stock worth $504,000 after acquiring an additional 569 shares in the last quarter. Bank of Montreal Can grew its holdings in PRA Health Sciences by 12.8% during the 3rd quarter. Bank of Montreal Can now owns 6,491 shares of the medical research company’s stock worth $715,000 after acquiring an additional 738 shares in the last quarter. Twin Tree Management LP grew its holdings in PRA Health Sciences by 59.7% during the 3rd quarter. Twin Tree Management LP now owns 2,058 shares of the medical research company’s stock worth $227,000 after acquiring an additional 769 shares in the last quarter. Finally, MML Investors Services LLC grew its holdings in PRA Health Sciences by 34.7% during the 3rd quarter. MML Investors Services LLC now owns 3,006 shares of the medical research company’s stock worth $331,000 after acquiring an additional 774 shares in the last quarter.

Shares of PRA Health Sciences stock opened at $101.31 on Monday. PRA Health Sciences Inc has a 12-month low of $79.00 and a 12-month high of $112.88. The company has a quick ratio of 0.89, a current ratio of 0.89 and a debt-to-equity ratio of 1.22. The firm has a market capitalization of $6.58 billion, a PE ratio of 31.66, a P/E/G ratio of 1.47 and a beta of 0.73.

PRA Health Sciences (NASDAQ:PRAH) last issued its earnings results on Wednesday, October 31st. The medical research company reported $1.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.07 by $0.06. PRA Health Sciences had a net margin of 2.37% and a return on equity of 25.75%. The business had revenue of $717.60 million during the quarter, compared to analysts’ expectations of $729.63 million. During the same quarter in the prior year, the business posted $0.88 EPS. The company’s revenue for the quarter was up 23.3% on a year-over-year basis. As a group, research analysts expect that PRA Health Sciences Inc will post 3.93 earnings per share for the current year.

PRAH has been the subject of several analyst reports. BidaskClub upgraded shares of PRA Health Sciences from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 25th. UBS Group initiated coverage on shares of PRA Health Sciences in a report on Tuesday, October 9th. They set a “neutral” rating for the company. Evercore ISI initiated coverage on shares of PRA Health Sciences in a report on Thursday, October 4th. They set an “inline” rating and a $120.00 price target for the company. Robert W. Baird boosted their price target on shares of PRA Health Sciences from $112.00 to $116.00 and gave the stock an “outperform” rating in a report on Tuesday, September 11th. Finally, KeyCorp reiterated a “buy” rating and set a $115.00 price target on shares of PRA Health Sciences in a report on Thursday, August 2nd. Two analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $111.50.

COPYRIGHT VIOLATION WARNING: “Vaughan Nelson Investment Management L.P. Has $36.72 Million Holdings in PRA Health Sciences Inc (PRAH)” was originally published by WKRB News and is owned by of WKRB News. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.wkrb13.com/2018/11/26/vaughan-nelson-investment-management-l-p-has-36-72-million-holdings-in-pra-health-sciences-inc-prah.html.

About PRA Health Sciences

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Further Reading: Marijuana Stocks Investing Considerations

Institutional Ownership by Quarter for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply